Growth Metrics

Ultragenyx Pharmaceutical (RARE) Current Leases (2019 - 2025)

Historic Current Leases for Ultragenyx Pharmaceutical (RARE) over the last 7 years, with Q3 2025 value amounting to $12.1 million.

  • Ultragenyx Pharmaceutical's Current Leases rose 1648.12% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year increase of 1648.12%. This contributed to the annual value of $10.3 million for FY2024, which is 1824.53% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Current Leases is $12.1 million, which was up 1648.12% from $11.8 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Current Leases ranged from a high of $12.8 million in Q1 2024 and a low of $9.4 million during Q1 2021
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Current Leases value was $11.3 million (recorded in 2022), while the average stood at $11.3 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Current Leases surged by 4198.13% in 2021, and later plummeted by 1824.53% in 2024.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Current Leases stood at $11.1 million in 2021, then rose by 6.44% to $11.8 million in 2022, then grew by 6.93% to $12.6 million in 2023, then dropped by 18.25% to $10.3 million in 2024, then rose by 17.92% to $12.1 million in 2025.
  • Its Current Leases was $12.1 million in Q3 2025, compared to $11.8 million in Q2 2025 and $10.5 million in Q1 2025.